Background {#Sec1}
==========

Tauopathies constitute a group of neurodegenerative disorders that include Alzheimer's disease (AD), progressive supranuclear palsy (PSP), Pick's disease, and others. These diseases are characterized by cerebral accumulation of the microtubule-associated protein tau \[[@CR1]\]. Tau is composed of three- or four-microtubule binding domains, depending on alternative splicing of exon 10, leading to the three-repeat (exon 10−) tau isoform (3R) and the four-repeat (exon 10+) tau isoform (4R). Alternative inserts near the N-terminus result in a total of six tau isoforms expressed under physiological circumstances \[[@CR2]\]. Mutations in the gene encoding tau, *MAPT*, can lead to different clinical disorders and neuropathologies, which have been found to depend on the mutation's location within the gene \[[@CR2]\]. Mutations in *MAPT* exons 9 and 11 and most mutations in exons 12 and 13 were associated with combined 3R and 4R tau pathology. Several mutations in exon 10 and all of the 5′ following intronic mutations inhibit alternative exon 10 splicing, leading to predominant 4R tau deposition in neurons as well as glial cells. Other *MAPT* mutations, including *MAPT* c.1216C \> T (p.Arg406Trp; R406W) in exon 13, however, did not affect the ratio of 3R to 4R tau isoforms in laboratory models, but they caused aggregations of all six forms of tau, more closely resembling the situation in AD \[[@CR2]\]. Clinical symptoms in patients with *MAPT* mutations are generally heterogeneous and designated as frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17~MAPT~). Patients with R406W develop clinical features of both AD and FTDP-17 \[[@CR3]\] and have brain deposition of tau as neurofibrillary tangles (NFTs), whereas amyloid-β (Aβ) pathology is only rarely present \[[@CR4]--[@CR6]\]. This makes FTDP-17~R406W~ an ideal candidate for studying human tau-only pathology.

In this study, we identified R406W in a large Swedish family with slowly progressive dementia. We present longitudinal radiological and clinical data derived from this novel kindred, including the neuropathology of three patients who died after various disease durations. We also systematically reviewed previously described R406W patients, aiming for a firmer determination of the typical clinical features of FTDP-17~R406W~. However, in contrast to previous results, all three neuropathologically examined members of the family in the present study showed PSP-like neuropathology with clear predominance of 4R over 3R tau.

Methods {#Sec2}
=======

Description of a new kindred {#Sec3}
----------------------------

In 1987, the kindred's proband (III-2) approached one of the authors (LG) because several family members had developed dementia. Family members were contacted after genealogical research in publicly available databases or through the proband, and symptomatic patients were enrolled. Seven affected family members (the proband and patients III-3, III-4, III-5, III-6, IV-9, and IV-16) were followed longitudinally for up to 22 years and were repeatedly examined by a specialist in memory disorders or neurology (LG, CN, or AP). Clinical data, including medical history, neurological and neuropsychiatric assessments, cerebrospinal fluid (CSF) analyses, and apolipoprotein E genotype were collected and compiled. For the other affected members, clinical data as provided by the family were collected.

Genetic analyses {#Sec4}
----------------

Blood was collected from a total of 14 family members, and DNA was extracted using standardized methods. Four affected family members (III-2, III-3, III-6, and IV-9) were examined by exome sequencing. Other samples were analyzed with TaqMan genotyping assays (Applied Biosystems, Foster City, CA, USA).

Imaging {#Sec5}
-------

Data on radiological examinations of affected family members performed during the course of the study and at admission were compiled and included computed tomography (CT) and magnetic resonance imaging results. Images were reevaluated in this research study by a neuroradiologist (DvW). Medial temporal atrophy was visually rated using the Scheltens (visual) rating scale \[[@CR7]\]. White matter hyperintensities, a common manifestation of small vessel disease, was quantified using the Fazekas scale \[[@CR8]\].

Neuropathology {#Sec6}
--------------

Autopsy was performed in three family members. Individual III-1 had died in the 1980s of colorectal cancer, and only four small tissue blocks of brain tissue were still available. In individuals III-3 and III-6, full-scale neuropathological examination was performed (by EE) \[[@CR9]\]. These brains were assessed macroscopically for regional atrophy and for vascular or other focal pathology, then cut into coronal whole-brain sections as well as into small samples comprising frontal, parietal, temporal, and occipital lobe cortices and white matter, central brain nuclei, limbic structures, brainstem, and cerebellum. After dehydration and paraffin-embedding, the blocks were sectioned at 5- and 4-μm thickness (large and small sections, respectively). Sections from all patients were then stained with conventional stains such as H&E and Luxol fast blue and counterstained with cresyl violet, stains for detection of protein deposits (modified Gallyas silver) and for Aβ (Congo red), as well as immunohistochemical stains targeting hyperphosphorylated tau (AT8; Dako, Glostrup, Denmark), tau isoforms 3R and 4R (anti-tau 3-repeat isoform RD3, 8E6/C11; EMD Millipore, Billerica, MA, USA; and anti-4R-tau, catalogue number TIP-4RT-P01; Cosmo Bio, Tokyo, Japan), α-synuclein (Zymed Laboratories, South San Francisco, CA, USA), and TAR DNA-binding protein (pTDP-43; Cosmo Bio). The tau sections were examined independently by two neuropathologists (EE and IA).

Systematic review {#Sec7}
-----------------

A systematic review of the R406W literature was performed by searching the PubMed database (latest search date 24 February 2017). Search terms used were "tau", "MAPT" or "Microtubule associated protein tau" in all possible combinations with "R406W", "Arg406Trp", "406", "1216", "1216C \> T" and "1216C-T". We included only peer-reviewed publications written in English. Reference lists of the retrieved studies were searched. Case reports and patient series regarding humans with R406W including clinical, radiological, or pathological data were selected for review by reviewing titles and abstracts, as well as, when there was uncertainty, full text. When there were several publications on the same kindred, individual information could be linked to the corresponding family member using data from pedigrees, clinical milestones, or personal communication with the authors. Individuals with no additional data than mutation status were excluded. When particular variables were not reported in a publication, this was marked in the resulting tables. Only descriptive nonparametric statistics were used.

Results {#Sec8}
=======

Description of a new Swedish kindred {#Sec9}
------------------------------------

Exome sequencing revealed an R406W mutation in patients III-3, III-6, and IV-9. This mutation was subsequently identified in all other affected family members for whom DNA was available, except the proband (III-2) who had developed dementia during the course of this study but in whom the mutation was excluded. The proband III-2 had onset of memory impairment at the age of 75, which was later than in the other affected family members (Table [1](#Tab1){ref-type="table"}). He was diagnosed with AD 2 years later and did not develop marked behavioral problems or Parkinsonism and was therefore considered to have sporadic AD and was excluded from the study. All other family members who did not carry the mutation were clinically unaffected. Four affected family members for whom no DNA was available were obligate mutation carriers (Fig. [1](#Fig1){ref-type="fig"}).Table 1Clinical data of patients with MAPT R406W mutation in a novel Swedish familyIdentifierR406WSexAoO, yearsDDClinical diagnosisAPOEEarly or presenting symptomsVisuospatialType of memory impairmentLanguage impairmentOther cognitive or behavioral symptomsLoI, psychiatric symptomsParkinsonism, other neurological findingsII-1(Mut)F709DDementia NOSN/AN/AN/AN/AN/AAggression and wandering behaviorN/AN/AIII-1N/AF572(d)NoneN/AN/AN/AN/AN/ASocial withdrawal^a^N/ANoneIII-3MutF5327DADε3/ε3Prosopagnosia^a^N/AEpisodicReduced output, echolalia (26)Shallow emotions (7), slight disinhibition, confabulationLoI (8), anxiety, paranoid tendenciesRigidity and bradykinesia (25), unexplained falls, dyskinesias in lower jawIII-4N/AM5817DADε4/ε4Memory impairmentImpairedEpisodic and semanticApraxia of speechDisinhibition, aggression and sexual suggestions (9), DV, wandering behavior, confabulationSevere LoINoneIII-5(Mut)M6314DN/AN/AN/AN/AN/AN/ADyscalculia, dysfunctional at household chores, mild behavioral symptoms (11) wandering behavior (11--14)Severe LoI, anxiety (14)NoneIII-6MutF5026DADε3/ε3Dyscalculia, social withdrawal, lack of initiativeMild Q, impaired (24)Learning difficultiesReduced spontaneous outputEmotional lability, DV (1), mood changes, perseverations, and confabulation (6), disinhibition, aggression and rude language (18), wandering behavior (24)LoI, anxietyBradykinesia, mild rigidity and dysdiadochokinesia (24), slight tremor^a^, dyspraxia of left hand, dysphagia^a^IV-9MutM5112(a)MCIN/AIrritability^a^, visuospatial difficulties^a^, short-term memory lossN/AShort-term memory lossDyslexia and dysnomia (5)Confabulation (5), irritabilityMild LoI, anxiety, emotional lability (5)NoneIV-16MutF526(a)NoneN/AAnxiety, memory impairmentQ (3)Episodic (3)NoDisinhibitionMild LoINone*Mut* R406W heterozygote, *(Mut)* Obligate carrier of R406W, *AoO* Age of (symptom) onset, *DD* disease duration, D indicates disease duration until death, (d) indicates death of an unrelated cause (cancer), and (a) alive, *APOE* Apolipoprotein E genotype, *NOS* Not otherwise specified, *AD* Alzheimer disease, *MCI* Mild cognitive impairment, *N/A* Not available, *LoI* Loss of insight, *DV* Déjà vu-like experiences (i.e. spontaneously recognizing an unknown place or person), *Q* qualitative impairmentNumbers in parentheses indicate disease duration at which particular symptom was reported^a^Self-reported or reported by relativesFig. 1Pedigree of a novel Swedish family with MAPT R406W mutation. *Circles* denote females, *squares* represent males, and *diamonds* indicate that sex was disguised; a *diagonal line* indicates a deceased family member; sibling order was changed, and in some branches, "n" indicates that the number of siblings is not specified, both to protect the family's confidentiality. *Solid black symbol* indicates individuals with dementia with age at onset before 71 years; *half-filled symbols* indicate dementia with a later age at onset or that clinical information was ambiguous. *Mut* R406W mutation detected by genetic testing, *(Mut)* Obligate R406W carrier, *Wt* Wild type (i.e., R406W mutation excluded by genetic testing). Additional individuals were tested genetically (not shown)

Individual clinical information from the other members of this family (those with the R406W mutation) is compiled in Table [1](#Tab1){ref-type="table"}. Median age of onset was 55 (IQR 51.25--61.75) years, and median disease duration, excluding patient III-1 because her cause of death (colorectal cancer) was considered unrelated to the disease, was 14 (IQR 9--26) years. Memory impairment was a marked symptom in all R406W carriers. Behavioral symptoms were present in all these family members but were mostly predominant in later disease stages and remained mild in several individuals. Other symptoms in this family included confabulation, déjà vu, substance abuse, impaired visuospatial functioning, and wandering behavior. Disease progression was slow (Table [1](#Tab1){ref-type="table"}), and individuals III-3, III-4, III-5, and III-6 did not move to a nursing home until 20, 11, 14, and 24 years after symptom onset, respectively. These four family members also retained the ability to play musical instruments up to 22 years after symptom onset. According to family history, individuals I-1 and I-2 both developed dementia with an escape-prone behavior and had been cared for at a community center for the elderly. Individual II-1 had slowly progressing memory deficits.

Patient III-6 was treated with cholinesterase inhibitors (ChEIs) for 17 years. Treatment effect was uncertain, although further clinical deterioration was documented after ChEI discontinuation. Combination with memantine was discontinued a few weeks after initiation, possibly owing to side effects. Individuals IV-9 and IV-16 have recently begun ChEI treatment.

Imaging {#Sec10}
-------

Radiological examinations were performed in six family members, with longitudinal data available from three (Fig. [2](#Fig2){ref-type="fig"}). Median disease duration at examination was 6 (IQR 2--20) years in our 6 novel cases compared with 6 (IQR 1--12.25) years for the 23 reviewed cases (Table [2](#Tab2){ref-type="table"}). A pattern was observed in the ventromedial temporal lobe (VMTL) in five family members, characterized by atrophy of the parahippocampal gyrus (PHG) with marked widening of the collateral sulcus (CS). The pattern was observed shortly after symptom onset and progressed over time (Fig. [2](#Fig2){ref-type="fig"}). Hippocampal atrophy was present in four family members but less pronounced than PHG atrophy. Thus the temporal atrophy in these patients differed from the typical pattern in AD, where medial temporal lobe atrophy primarily involves the hippocampus with widening of the choroid fissure. In addition, there was general atrophy that increased over time and may be related to both age and disease duration. Individuals IV-9 and III-1 had L \> R asymmetric lateral temporal lobe atrophy reminiscent of semantic dementia (SD).Fig. 2Radiological progression of MAPT R406W-related neurodegeneration. Longitudinal radiological examinations showed increasing ventromedial temporal lobe atrophy with widening of the collateral sulcus (*arrowheads*) as a characteristic and early sign. Hippocampal atrophy was also seen but was only relatively mild to moderate or became obvious only later in the disease course. *DD* Duration of disease at examinationTable 2Radiological findings in carriers of MAPT R406WIDSexModality (n)DD, yearsAtrophy patternTemporal lobe atrophyHippocampusParahippocampal gyrusCollateral sulcusSymmetryVascular pathologyQualityPresent studyIII-1F(1) CT2TM 2^a^L \> R0^b^--^c^III-3F(1) CT28General2^a^Advanced atrophyYes2^b^--^c^III-5M(1) CT6GeneralM 2^a^WidenedYes0^b^ + 6-mm lacunar infarction--^c^III-6F(1) MRI20General, TM++ (L \> R)Advanced atrophyWidenedYes0^b^+(1) CT26General P, TM 3^a^Advanced atrophyWidened PYes0^b^++IV-16F(1) CT1Slight TSlight MNoWidenedYes0^b^--^c^(1) MRI4T, PM P 1^a^Widened PYes0^b^++IV-9M(2) CT5, 9General, TGeneralAtrophy PWidened PL \> R1^b^(2) MRI10, 10General, T, F ParietalGeneral 1^a^Atrophy PWidened PL \> R1^b^+++van Swieten et al. \[[@CR19]\]1F(1) MRI4Mild FTN/RN/RN/RN/RL \> RN/RN/R2M(1) MRI5Mild FTN/RN/RN/RN/RL \> RN/RN/RPassant et al. \[[@CR42]\]III:1F(2) MRI1--4TM and AAtrophyN/RN/RYesN/RN/RIII:2M(2) MRI1--4TM and AAtrophyN/RN/RYesN/RN/RIII:3M(2) MRI1--4TM and AAtrophyN/RN/RYesN/RN/RIII:4M(2) MRI1TM and AAtrophyN/RN/RYesN/RN/RLindquist et al. \[[@CR4]\]III/1F(1) CTN/RCentralN/RN/RN/RN/RN/RN/RN/RIII/3F(1) CTN/RTN/RN/RN/RN/RYesN/RN/RIV/2F(1) MRIN/RTSuperficial MN/RN/RN/RN/RN/RN/RIkeuchi et al. \[[@CR43]\]P3367-1M(1) MRIN/RTM onlyAtrophyAtrophyN/RYesN/RN/RP3367-2M(1) MRIN/RTMN/RN/RN/RYesN/RN/RP3367-3F(1) MRIN/RTMN/RN/RN/RYesN/RN/RP3048-1F(1) MRI15TMN/RN/RN/RYesN/RN/RP3048-2F(1) MRIN/RTMN/RN/RN/RYesN/RN/RP4550-1F(1) MRI9TMN/RN/RN/RYesN/RN/RHirschbichler et al. \[[@CR3]\]1F(1) MRI0--1NormalN/RAsymmetricN/RN/RHippocampal asymmetryN/RN/RReed et al. \[[@CR10]\]IV-2M(1) MRI0NormalN/RN/RN/RN/RN/RN/RN/RKomatsu et al. \[[@CR44]\]1M(1) MRI1Mild FTN/RAtrophyN/RN/RN/RN/RN/RTolboom et al. \[[@CR12]\]1M(1) MRI7Pronounced TM and AAtrophyN/RN/RYesN/RN/R2F(1) MRIN/RTMAtrophyN/RN/RN/RN/RN/RIshida et al. \[[@CR6]\]1M(1) MRIN/RFTN/RN/RN/RN/RN/RN/RN/R(1) CTN/RTN/RN/RN/RN/RYesN/RN/RWood et al. \[[@CR17]\]1FMRI12TN/RN/RN/RN/RR \> LN/RN/R2FMRI (\>1)13T, PN/RN/RN/RN/RR \> LN/RN/R*DD* Disease duration at examination, *P* Progressive, *T* Temporal, *M* Medial, *A* Anterior/ventral, *FT* Frontotemporal, *MRI* Magnetic resonance imaging, *CT* Computed tomography, *N/R* Not reported^a^Medial temporal atrophy assessed with Scheltens scale (0--4)^b^Assessed with Fazekas scale (0--3)^c^Reduced quality due to thick slices or artefacts

Individuals IV-9, IV-16, and III-6 of this study have been examined by ^18^F-AV-1451 tau-positron emission tomography (PET) in another study revealing tracer uptake in frontotemporal areas and the hippocampus \[[@CR9]\].

Neuropathology {#Sec11}
--------------

Autopsy of patient III-3, who died after 27 years of disease (brain weight 940 g), macroscopically showed atrophy in the frontal lobes and more severe atrophy bitemporally, especially pronounced in the PHG, accompanied by a marked dilation of the IIIrd and IVth ventricles, as a sign of atrophy within the region of central nuclei and the brainstem, respectively. The hippocampus exhibited severe atrophy, with a remaining size of 4 × 2 mm in the midhippocampal region, coronal plane. Microscopically, there was severe cortical degeneration with neuronal loss and gliosis in the VMTL, including the entorhinal region, where it was most marked in the PHG, creating a markedly widened CS. The amygdala was degenerated, whereas within the hippocampus, the overall severe cell loss was accentuated in Cornu Ammonis (CA)1. There was marked neuronal loss and gliosis of basal ganglia, most pronounced in the globus pallidus. The insular cortex, the thalamus, and the subthalamic nucleus harbored significant tau pathology. Brainstem nuclei were markedly degenerated with cell loss and depigmentation, especially the locus coeruleus and substantia nigra.

Immunoreactivity against hyperphosphorylated tau was intensive in all the areas examined where there was neuronal loss, and there were abundant silver-positive NFTs (Table [3](#Tab3){ref-type="table"}). There was marked white matter degeneration also in the temporal lobe, with widespread tau-positive axonal fragments. In this individual, TDP-43 immunoreactivity was seen, appearing as large cytoplasmic granular inclusions in neurons; fewer but otherwise similar inclusions were present in glial cells in the gray matter and in the white matter.Table 3Neuropathological features of MAPT R406W patientsKindredPatient (DD)Neuronal tauGlial tauUltrastructure of tau filamentsTau biochemistry/isoformsAmyloidα-SynucleinInterpretationMidwest American/FTD004 family \[[@CR10], [@CR31], [@CR32], [@CR34]\]1 (30)NFT, NT, globose tanglesOccasional astrocytes (tangle-like inclusions)PHFSix fractions; both wild-type and mutated tau in depositsNonePSPDutch family \[[@CR5], [@CR19], [@CR31], [@CR33], [@CR45]\]1 (13)NFT, some pretangles, dystrophic neurites, NT, a few PBOccasional glial cellsPHF and SF3R and 4R isoforms; both wild-type and mutated tau in deposits, 4R \< 3RDP (low density), no congophilic plaques, no angiopathyNone2 (13)NFT, NT, diffuse/amorphous cytoplasmic tau depositsNonePHF as in AD, and SF (minority of filaments)3R and 4R isoforms; six fractions; both wild-type and mutated tau in deposits, ghost tanglesNP (moderate density)Japanese family 1 \[[@CR46]\]1NFT, NTOligodendroglial coiled bodies (only Gallyas-Braak staining reported)N/ABoth wild-type and mutated tau in deposits; widespread ghost tanglesNoneNoneFeatures of PSP/CBD/tangle-only dementiaU.S. family 2 \[[@CR35]\]1NFT, NT, no PBNoneN/A3R and 4R isoformsNoneNo LBNFT dementiaDanish family \[[@CR4]\]1NFT, NT, no PBOccasional glial cells (fibrillary inclusions)N/A3R and 4R isoforms; 4R \< 3RNP (CERAD A); many DPNoneJapanese family 2 \[[@CR6]\]1NFT, NT, PB-like inclusions (or globose tangles)Cytoplasmic immunoreactivity in gliaN/A4R \< 3R isoforms; 3R-positive ghost cellsNP (CERAD C); many DPU.S. family 3 (ZKW, personal communication)1 (29)NFT, NTN/A3R and 4R isoformsNPADU.K. patient \[[@CR17]\]1NFT, PBAstrocytic plaquesN/RN/RN/RN/RN/RSwedish family (present report)III:1 (2)NFT, NT, neuritesTufted astrocytesN/A4R \> 3RNoneNonePSP-like dementia (minimal material)III:3 (27)NFT, NT, neuritesTufted astrocytes, glial plaquesN/A4R \> 3RNoneNonePSP-like dementiaIII:6 (26)NFT, NT, neuritesTufted astrocytesN/A4R \> 3RNoneMinimal (focal in CA2)PSP-like dementia*AD* Alzheimer's disease, *3R tau* Three-repeat (exon 10−) tau isoform, *4R tau* Four-repeat (exon 10+) tau isoform, *CA* Cornu Ammonis area, *CERAD* Consortium to Establish a Registry for Alzheimer's Disease, *DD* Duration of disease, *PHF* Paired helical filaments, *SF* Straight filaments, *NFT* Neurofibrillary tangles, *NT* Neutrophil threads, *PB* Pick bodies, *NP* Neuritic plaques, *DP* Diffuse plaques, *Six fractions* All six insoluble tau fractions detected, *CBD* Corticobasal dementia, *LB* Lewy bodies

The neuropathology of patient III-6, who died after 26 years of disease (brain weight 1085 g), revealed atrophy in the frontal and temporal lobes, more markedly in the latter, as well as dilation of the third and fourth ventricles and atrophy of the brainstem, similar to the macroscopic findings of patient III-3. Microscopically, there was neuronal loss and gliosis in a distribution pattern similar to that of patient III-3, with the majority of pathological changes seen in the basal temporal lobes, including the hippocampus, the central nuclei, and the brainstem nuclei. Also in this patient, there was involvement of cerebral white matter. Tau immunoreactivity was marked owing to NFTs in cortical neurons, the thalamus, PHG, and hippocampi (especially in the dentate fascia), and there were some tufted astrocytes. In the white matter, there were tau-positive depositions in neurites, axonal fragments, and some glial inclusions. The tau-immunoreactive changes were most pronounced in the temporal lobes, clearly evident in the frontal lobes and basal ganglia, less pronounced in the parietal and occipital lobes, and only sparsely in the cerebellum. There was focal α-synuclein-positive pathology with Lewy bodies and Lewy neurites, regionally confined to the hippocampal CA2, where there also was pyramidal cell loss.

Patient III-1 died of colon adenocarcinoma 2 years after onset of memory problems. There were no metastases to the brain. Autopsy was performed in the 1980s. The limited tissue blocks available for reassessment in the present study did not allow a comparison with the areas of maximal macroscopic atrophy on imaging, but they exhibited mild neuronal degeneration in sections representing the midbrain and neocortex (specific area not known). These areas stained densely positive for tau, as did the subjacent white matter.

All three patients assessed neuropathologically had abundant 4R pathology in cells and dystrophic neurites, as well as much less intense and less widespread 3R immunohistochemical staining positivities, which were confined to a few neurons (Fig. [3](#Fig3){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}). No brain Aβ was detected. There were many globose NFTs in the cortex, and in patients III-3 and III-6, globose NFTs were also noted in the hippocampus, as well as many tau-positive axonal fragments in the white matter, but there was a less prominent appearance of tufted astrocytes and fewer coiled bodies.Fig. 3Neuropathology. Photomicrographs of cortical, white matter, and hippocampal sections from three family members. Individuals, immunohistochemistry, and enlargement are as indicated. All three patients had abundant tau pathology in the cortex and white matter, with a marked predominance of four-repeat (exon 10+) tau isoform immunoreactivity. *3R tau* Three-repeat (exon 10−) tau isoform. *4R* *tau* Four-repeat (exon 10+) tau isoform

Among the autopsied family members, both III-3 and III-6 carried the H1/H2 tau haplotype. No DNA was available for the third autopsied individual, III-1. Patient IV-9 also showed H1/H2 (Additional file [2](#MOESM2){ref-type="media"}).

Systematic review {#Sec12}
-----------------

Clinical data on 66 R406W patients were compiled from the literature (Table [4](#Tab4){ref-type="table"}, and Additional files [3](#MOESM3){ref-type="media"} and [4](#MOESM4){ref-type="media"} for individual clinical data and cerebrospinal fluid examinations). The reports were published between 1997 and 2017, and methods of ascertainment, patient evaluation, and reporting varied. Median age of onset was 55.5 (IQR 51.25--59.75) years, and median disease duration reported at last examination or death was 13 (IQR 11--21) years. Onset of memory impairment was reported as early in 59% of the reviewed cases. Onset of visuospatial impairment was in the first years of disease for two patients \[[@CR10], [@CR11]\] and reported as gradual in four additional patients \[[@CR11]\]. Behavioral symptoms developed in 42.4%, but Parkinsonism developed in only 16.7% of reviewed cases. These symptoms were present at disease onset in only 22.7% and 4.5% of the reviewed cases, respectively. Prosopagnosia was reported to have occurred 7 and 24 years after symptom onset in two reviewed cases \[[@CR10], [@CR12]\]. Reported R406W homozygotes had much earlier symptom onset and earlier and more pronounced behavioral symptoms and Parkinsonism; one homozygous patient also had paranoid delusions, hyperreligiosity, and compulsive behavior \[[@CR13], [@CR14]\].Table 4Systematic review of descriptions of MAPT R406W patientsReferencesNo. of subjectsSexAoO^a^, yearsDur^a^, yearsDiagnosis^b^APOEEarly memory loss (*n*)Early BS (*n*)Visuospatial impairment (*n*)Language impairment (*n*)BS (*n*)Psychiatric symptoms (*n*)Parkinsonism (*n*)Other (*n*)\[[@CR10]\]107 M, 3 F5425N/RN/R7111Aggression 1, Poor judgment and drifting 1Alcoholism 2BK, rigidity^c^, action T and mild rest T (arms) 1No vertical gaze, hypometric saccades, PR 1\[[@CR19], [@CR33], [@CR45]\]51 M, 4 F5713N/Rε3/ε4 133"Mostly intact" 3Para, pers, flu, mutism 2N/RN/RN/RN/R\[[@CR11]\]6^d^N/R5811EOAD 4, MCI-EOAD 1ε3/ε3 3, ε3/ε4 24155Withdrawal and adapting difficulties 1, Dis 1Depr and anxiety 1, emotional shallowness 2Rigidity, cogwheeling 4, T 3, BK 1, gait disturbance 1, total Parkinsonism 4Dysphagia 1, PR 1\[[@CR42], [@CR47]\]53 M, 2 F5623N/RN/R54NormalWord comprehension 3, stereotypies 3, flu 3, mutism 1Dietary change 4, dis 2, stereotypies 2, childish 2Restlessness 3, depr 1, anxiety 1, suspiciousness 2, emotional shallowness 4NoN/R\[[@CR4]\]30 M, 3 F65N/RAD 2, MCI 1ε3/ε2 1, ε3/ε3 1, ε3/ε4 13N/RN/RN/R2N/RN/RN/R\[[@CR14], [@CR48]\]8^ff^5 M, 2 F^ee^AD 1N/RN/R1^f^N/RAnomia 2^f^, para 1, comp, flu phonemic and semantic errors impaired word finding, poor spelling and aphasia 1^e^Apathy 1^f^N/R1^f^N/R\[[@CR3]\]10 M, 1 F56N/RN/RN/R111N/RDis and apathyN/RRest T (R), postural T (bilat), mild BK (L \< R), mild rigidity (L \< R), and mild dystoniaN/R\[[@CR49]\]11 M, 0 F50N/RN/Rε3/ε31N/RN/RN/RN/RN/RN/RN/R\[[@CR44]\]11 M, 0 F66N/RN/RN/R1N/RN/RN/RN/RN/RN/RNo\[[@CR35]\]10 M, 1 F5413Dementia NOSε3/ε3N/RN/RN/RN/RN/RN/RN/RN/R\[[@CR43], [@CR50], [@CR51]\]62 M, 4 F52.5N/REOAD 2, familial AD 1ε3/ε2 2, ε3/ε3 2, ε3/ε4 261N/RN/RLoss of interest 1, dis 2, mild 1Disorientation 1No 6N/R\[[@CR46]\]11 M, 0 F476Schizophrenia, primary degenerative dementiaε3/ε3N/RNoN/RN/RSelf-neglectPdel diminished appetite and severe confusionN/RN/R\[[@CR6]\]11 M, 0 F5914ADN/R1NoN/RSensory aphasiaViolent, angry, aimless walking, stereotypicApraxia, delusional mistakesNoN/R\[[@CR12]\]21 M, 1 F56.5N/RMCI 1, AD 1N/R2N/RN/RN/RN/RN/RN/RN/R\[[@CR52]\]6N/R57.511,5AD 2, dementia NOS 1N/R6N/RN/R55N/RN/RN/R\[[@CR13]\]5^f^N/R60--70^e^N/RAD 2ε3/ε3 1^f^N/R1^f^Prosopagnosia 1^f^Word finding, comprehension and speech output 1^f^Dietary change, argumentative, and dis 1^f^Depr^g^, Pdel, hyperreligiosity, compulsory routines, hoarding & Irritability 1^f^Masked faces and mild BK 1^f^, total Parkinsonism: 4^f^Slow saccades and square wave jerks^f^\[[@CR17]\]31 M, 2 F5413N/RN/RN/R2Prosopagnosia 2Dysnomia 2, repetitive 1Dietary change 2, stereotypies 1N/RNoN/R\[[@CR53]\]11 M, 0 F3826BvFTDN/RN/RN/RN/RN/RN/RObsessive, hoardingN/RN/RSummary66^d,fff^25 M, 23 F55 (IQR 51.25--59.75)13 (IQR 11--21)AD 17, any 23Any ε4 53913^h^620^h^26^h^139^h^3*AoO* Median age of onset of individuals reported, *Dur* Duration of disease, *BS* Behavioral symptoms, *AD* Alzheimer's disease, *EO* Early onset, *MCI* Mild cognitive impairment, *Dementia NOS* Dementia not otherwise specified, *BvFTD* Behavioral variant frontotemporal dementia, *APOE* Apolipoprotein E genotype, *Depr* Depression, *Dis* Disinhibition, *ADL* Activities of daily living, *Para* Paraphasias, *Pdel* Paranoid delusions, *Pers* Perseverations, *PR* Primitive reflexes (e.g., snout, grasp, rooting or palmomental), *Flu* Reduced verbal fluency or output, *Comp* Compulsive repetition of words, *BK* Bradykinesia, *T* Tremor^a^Reported as median of individual cases^b^Clinical diagnosis/diagnosis prior to genetic testing^c^Possible pharmacological cause (neuroleptics)^d^Including one R406W carrier with subjective memory deficit^e^Unsatisfactorily reported to be added to summary^f^Each superscript letter f indicates one confirmed MAPT R406W homozygote^g^Reported prior to onset of cognitive impairment^h^Summary of status of MAPT R406W heterozygotes but not homozygotes

Radiological and neuropathological data of previously described cases were compiled (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). Stabilized clinical progression and positive fludeoxyglucose-PET measurement was reported in one patient after memantine treatment \[[@CR4]\]. Neuropathological examination was performed in nine reviewed cases. Four had tau-only pathology, but five showed co-occurring Aβ pathology, including several cases with observed concomitant positive immunohistochemistry for Aβ and ubiquitin (Table [3](#Tab3){ref-type="table"}).

CSF examinations {#Sec13}
----------------

Results of CSF examinations were available for three members of the novel Swedish kindred and six reported cases in the literature and showed a trend for increased levels of CSF tau and phosphorylated tau in about half of R406W patients, but normal levels of CSF Aβ~1--42~ (Additional file [4](#MOESM4){ref-type="media"}).

Discussion {#Sec14}
==========

We present a novel Swedish R406W kindred with markedly slowly progressive dementia, as well as a systematic review of previous reports on FTDP-17~R406W~ patients. The clinical phenotype of patients with this mutation consists predominantly of memory loss and varying or gradual development of frontotemporal dementia (FTD)-like cognitive dysfunction. Radiological examinations of FTDP-17~R406W~ patients reveal progressing atrophy that starts in the VMTL and spreads to adjacent regions over time. Neuropathology shows a pattern of regional degeneration and accumulation of NFTs. Although previously reported individuals with this mutation had both 3R and 4R tau pathology, all three autopsied members of the present family had a PSP-like pathology, with a regional spread of degeneration and with marked predominance of 4R over 3R, but without some of the other PSP-characteristic traits.

Limitations {#Sec15}
-----------

The major limitation of this study is the small size of our cohort and the low quantity of verified R406W cases in the literature. The review might be influenced by publication or selection biases as well as differences in reporting and grading of symptoms between authors. A common problem with neurogenetic diseases is the rarity of specific point mutations \[[@CR15]\]. This is an important issue because larger cohorts will probably be needed to explain the observed and not yet fully understood clinical heterogeneity of patients with *MAPT* mutations.

Clinical features {#Sec16}
-----------------

Although there is large intra- and interfamilial clinical variability in all FTDP-17~MAPT~ \[[@CR2]\], R406W patients often first develop memory impairment. Parkinsonism occurred rarely at end-stage disease in the novel Swedish family, and many patients in this and other families with FTDP-17~R406W~ received an initial clinical diagnosis of AD. Disease progression was remarkably slow (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}), and age of onset is later than for patients with most other *MAPT* mutations \[[@CR2]\]. In the novel Swedish family, déjà vu and confabulation, previously described in dementia cases with predominant temporal lobe atrophy \[[@CR16]\], developed in 50% of cases. As the disease progressed, more symptoms typically associated with FTD developed, such as disinhibition, wandering behavior, and aggression. More severe disease was present in all of the more recently described homozygous R406W patients, suggesting a dose-dependent and direct effect of R406W mutated tau \[[@CR13], [@CR14]\].

Radiological features {#Sec17}
---------------------

Atrophy in our novel R406W cases was initially seen in the VMTL, with atrophy of the PHG and secondary widening of the CS as a consistent, early, and progressive pattern. Throughout the disease course of these patients, VMTL atrophy remained more pronounced than hippocampal atrophy, which was observed only late. Thus, the pattern of atrophy in our R406W cases differed from the typical AD pattern. Any assessment of diagnostic or prognostic value of this finding was considered beyond the scope of this work, and confirmation is needed. We suggest, however, that relatively isolated PHG atrophy and CS widening should raise suspicion of FTDP-17~MAPT~ and especially FTDP-17~R406W~. Because radiologists may tend to describe either medial or lateral temporal lobe atrophy, and because neither atrophy of the PHG nor associated widening of the CS is incorporated in the Scheltens (visual) rating scale \[[@CR7]\], there may be underreporting of more predominant VMTL atrophy, and/or localized changes affecting only CS or PHG, in other tauopathies.

FTDP-17~R406W~ disease can sometimes manifest with asymmetric temporal lobe atrophy \[[@CR17]\], and left (dominant) lateral temporal lobe atrophy has rarely been reported in FTDP-17~R406W~ patients \[[@CR2], [@CR18], [@CR19]\]. Clinical SD symptoms in addition to FTD phenotype, however, have been more commonly reported in FTDP-17 patients with other *MAPT* mutations \[[@CR20]\]. Temporal lobe atrophy with left-sided dominance, as in SD, was found radiologically in patients III-1 and IV-9. The unrelated and early death of patient III-1 prevented detailed characterization of clinical symptoms, but patient IV-9 had dysnomia and misunderstood or forgot instructions despite relatively short disease duration. This supports the possibility of an SD-similar phenotype in FTDP-17~R406W~.

This is the first study to report mainly 4R tau pathology in FTDP-17~R406W~ patients, which contrasts with previous findings \[[@CR2]\]. It has been suggested that the pattern of temporal lobe atrophy differs, depending on the location of the *MAPT* mutation, with regard to the effect on exon 10 alternative splicing \[[@CR21]\]. Medial temporal lobe atrophy is found more often in patients with IVS10 + 3, IVS10 + 16, p.N279K, and p.S305N mutations, which affect exon 10 splicing and lead to expression of only 4R tau. Lateral temporal lobe atrophy was reported in p.P301L and p.V337M cases, where both 3R and 4R tau are expressed \[[@CR2], [@CR21]\].

Neuropathological features {#Sec18}
--------------------------

In the novel Swedish family, individuals III-1, III-3, and III-6 had tau depositions in cortical neurons and in white matter, which were most pronounced in the temporal lobe. In particular, the widening of the CS, as seen with imaging, prevailed as a prominent detail also demonstrated postmortem (Additional file [1](#MOESM1){ref-type="media"}). The temporolimbic region was thus particularly affected (when available for neuropathological examination; patient III-3 and III-6), and furthermore, the locus coeruleus had a high tau load and was highly atrophic. These findings are consistent with the clinical similarities between R406W-associated disease and AD. In the hippocampi of patients III-3 and III-6, CA1 neurons were severely affected, similar to both PSP and AD. The severity of the central atrophy exceeded that seen in other tauopathies, except in severe forms of PSP. This unequally spread atrophy might stand for a slow and unique distribution of pathology caused by R406W mutated tau.

Immunohistochemical staining in the novel family showed the presence of both 3R and 4R tau isoforms. However, 4R tau staining was clearly more abundant, and 3R tau was judged to be at nearly physiological levels for age (Fig. [3](#Fig3){ref-type="fig"}). The pathological picture in the Swedish family was reminiscent of PSP also in aspects other than 4R predominance: (1) the presence of neuronal NFTs and, albeit scarce, of tufted astrocytes and occasional coiled bodies \[[@CR22], [@CR23]\]; (2) prominent tau white matter pathology, and (3) marked involvement of the brainstem and central nuclei. However, the cortical load of tau-positive threads and neurons was more dense and severe than seen in typical PSP \[[@CR22]\]. This may hypothetically be an effect of the disease process allowed to develop during an unusually long time. Hereditary PSP is rare, but families with more than one member with pathologically proven PSP have been described, including a family harboring an MAPT p.S285R mutation \[[@CR24]\].

Other genetic or environmental factors can probably modify neurodegenerative features in human tauopathies. The H1 *MAPT* haplotype increases PSP risk and has been associated with higher expression of 4R tau, but it is too common in the general population to explain the unusual 4R tau predominance in the present family \[[@CR25]--[@CR27]\] and has previously been shown not to influence the phenotype of FTDP-17 patients with other *MAPT* mutations \[[@CR28]\]. A more complex interaction between the R406W mutation and other genetic variability in the H1/H2 clades cannot be excluded. It has also been shown that the pathology of PSP changes with regard to disease duration \[[@CR29]\], and in AD, the predominance of either the 4R or 3R isoform of tau pathology similarly depends on disease duration; however, more 4R tau was present in early than in late AD stages \[[@CR30]\].

Aggregation of tau and subsequent atrophy in our R406W patients was most pronounced in the VMTL area. The transentorhinal region is also prominently affected by tau pathology with NFT accumulation in early idiopathic AD, and additional findings overlap between AD and FTDP-17~R406W~, including clinical symptoms, expression of all isoforms of tau with laboratory findings of a 3R/4R ratio close to 1, ultrastructural composition of tau in paired helical filaments, with a minority of short filaments \[[@CR4], [@CR31]--[@CR35]\]. Furthermore, R406W mutated tau has been shown to increase its toxicity in the presence of Aβ \[[@CR36]\]. The locus coeruleus may be an even earlier starting point for tau pathology in AD \[[@CR37]\] and was severely affected by tau pathology in patients III-3 and III-6. Aβ pathology was found in five FTDP-17~R406W~ patients, four of whom had neuritic plaques (\[[@CR4]--[@CR6]\]; ZKW, personal communication). Interestingly, Aβ levels have been shown to be increased to just below the plaque formation threshold in the brains of patients with FTD with *MAPT* mutations \[[@CR38]\]. NFT formation in the VMTL is also a hallmark in primary age-related tauopathy (PART), formerly named *tangle-only dementia*. Aβ deposition is believed never to ensue in PART \[[@CR35]\], which is presumed to be a more purely age-related NFT pathology \[[@CR39]\], but its role as an entity distinct from AD is debated \[[@CR40], [@CR41]\]. Despite the many similarities between FTDP-17~R406W~ and AD, our understanding is that FTDP-17~R406W~ tauopathy is more clearly distinct from AD than PART is, owing to the genetic basis of the disease. The above-mentioned similarities might thus imply dual pathogenic mechanisms rather than comorbidity.

Conclusions {#Sec19}
===========

FTDP-17~R406W~ is a distinct disease entity that clinically shares features with AD, but in a novel Swedish family we found it to be associated with PSP-like, predominant 4R tau pathology, most pronounced in the VMTL, and we found a persistent and characteristic imaging pattern of VMTL atrophy. This disease provides an interesting model for the pathomechanisms of tau pathogenesis in humans.

Additional files
================

 {#Sec20}

Additional file 1: Figure S1.Additional neuropathology. Additional photomicrographs from three family members. Individuals, immunohistochemistry, and enlargement as indicated. (TIF 11179 kb) Additional file 2: Table S1.*MAPT* haplotype determination based on exome sequencing data. Individuals, residues, and haplotype as indicated. Note that the proband, individual III-2, had Alzheimer's disease and was excluded from the study. (PDF 181 kb) Additional file 3: Table S2.Individual data from previous publications (systematic review). Numbers indicate disease duration at first reported or observed symptom. Data in parentheses are successive or vaguely specified development or data unspecifically described. \*Symptoms reported by patient or relative. ^\#^Unreliable data owing to possible pharmacological cause (neuroleptics). ^§^Data too imprecisely reported to be included in calculations. *AD* Alzheimer's disease, *MCI* Mild cognitive impairment, *Dementia NOS* Dementia not otherwise specified, *CSF* Cerebrospinal fluid, *Aβ*~*42*~ Amyloid-β 1--42, *APOE* Apolipoprotein E, *ADL* Activities of daily living. (PDF 161 kb) Additional file 4: Table S3.Cerebrospinal fluid examinations. Numbers in parentheses indicate disease duration when cerebrospinal fluid was retrieved. *Upward filled triangles* = value above laboratory's reference value for healthy individuals; *downward filled triangles* = value below laboratory's reference value for healthy individuals. ^a^Compared with healthy control subjects (157 ± 65 pg/ml, *n* = 24) and patients with AD (555 ± 248 pg/ml, *n* = 31). ^b^Compared with healthy control subjects (29 ± 10 pg/ml, *n* = 21) and patients with AD (86 ± 39 pg/ml, *n* = 31). *N/A* Not assessed. (PDF 304 kb)
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:   Three-repeat (exon 10−) tau isoform

4R tau

:   Four-repeat (exon 10+) tau isoform

Aβ

:   Amyloid-β

AD

:   Alzheimer's disease

ADL

:   Activities of daily living

AoO

:   Age of onset

APOE

:   Apolipoprotein E

BK

:   Bradykinesia

BS

:   Behavioral symptoms

BvFTD

:   Behavioral variant frontotemporal dementia

CA

:   Cornu ammonis

CBD

:   Corticobasal degeneration

CERAD

:   Consortium to Establish a Registry for Alzheimer's Disease

ChEI

:   Cholinesterase inhibitor

Comp
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CS

:   Collateral sulcus

CSF

:   Cerebrospinal fluid

CT

:   Computed tomography

DD

:   Duration of disease

Dementia NOS

:   Dementia not otherwise specified

Depr

:   Depression

Dis

:   Disinhibition

DP

:   Diffuse plaques

DV

:   Déjà vu-like experiences (i.e., spontaneously recognizing an unknown place or person)

EO

:   Early onset

EOAD

:   Early-onset Alzheimer's disease

Flu

:   Reduced verbal fluency or output

FTD

:   Frontotemporal dementia

FTDP-17

:   Frontotemporal dementia with Parkinsonism linked to chromosome 17

LB

:   Lewy bodies

LoI

:   Loss of insight

MCI

:   Mild cognitive impairment

MRI

:   Magnetic resonance imaging

Mut

:   R406W heterozygote

(Mut)

:   Obligate carrier of R406W

NFT

:   Neurofibrillary tangle

NP

:   Neuritic plaques

NT

:   Neutrophil threads

Para

:   Paraphasias

PART

:   Primary age-related tauopathy

PB

:   Pick bodies

Pdel

:   Paranoid delusions

Pers

:   Perseverations

PET

:   Positron emission tomography

PHF

:   Paired helical filaments

PHG

:   Parahippocampal gyrus

PR

:   Primitive reflexes

PSP

:   Progressive supranuclear palsy

Q

:   qualitative impairment

SD

:   Semantic dementia

SF

:   Straight filaments

T

:   Tremor

VMTL

:   Ventromedial temporal lobe
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